Literature DB >> 29777409

Hemodynamic heterogeneity of connective tissue disease patients with borderline mean pulmonary artery pressure and its distinctive characters from those with normal pulmonary artery pressure: a retrospective study.

Yusa Asari1, Yoshioki Yamasaki2, Kosei Tsuchida1, Kengo Suzuki3, Yoshihiro J Akashi3, Takahiro Okazaki1, Shoichi Ozaki1, Hidehiro Yamada4, Kimito Kawahata1.   

Abstract

To clarify whether patients with connective tissue disease (CTD)-associated borderline mean pulmonary artery pressure (mPAP) have distinctive hemodynamic characteristics from those with normal mPAP and whether pathogenesis is as heterogeneous as manifest pulmonary hypertension (PH). Seventy-five CTD patients who underwent right heart catheterization (RHC) from 2008 through 2016 were retrospectively analyzed. We compared between-group differences in clinical and hemodynamic findings: normal mPAP (n = 35), borderline mPAP (n = 15), and PH (n = 25). A therapeutic intervention trial based on RHC results was performed in nine patients. The values of tricuspid regurgitation pressure gradient (TRPG) in patients with borderline mPAP were comparable at rest but became higher after exercise compared to those with a normal mPAP (P = 0.01). Pulmonary artery wedge pressure in patients with borderline mPAP was higher than in those with normal mPAP (P < 0.0001) and comparable to those with PH. Each of the three patients was treated for pre-capillary and post-capillary disease and two for interstitial lung disease (ILD). During the mean follow-up period of 40 months, mPAP or TRPG normalized in all patients treated for pre-capillary and post-capillary disease. One patient with severe ILD developed to PH and died from it. CTD patients with borderline mPAP, the underlining pathogenesis of which is heterogeneous as PH, have distinctive hemodynamic characteristics from those with normal mPAP. Whether a specific treatment targeting the inflammatory process or local hemodynamics may alter the clinical course to PH is a topic for future research.

Entities:  

Keywords:  Borderline mean pulmonary artery pressure; Connective tissue diseases; Left heart disease; Pulmonary arterial hypertension

Mesh:

Year:  2018        PMID: 29777409     DOI: 10.1007/s10067-018-4142-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward.

Authors:  Edmund M T Lau; Alessandra Manes; David S Celermajer; Nazzareno Galiè
Journal:  Eur Heart J       Date:  2011-05-26       Impact factor: 29.983

3.  Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.

Authors:  Gabor Kovacs; Robert Maier; Elisabeth Aberer; Marianne Brodmann; Winfried Graninger; Xhylsime Kqiku; Stefan Scheidl; Natascha Tröster; Christian Hesse; Lewis Rubin; Horst Olschewski
Journal:  Arthritis Rheum       Date:  2011-11-11

Review 4.  Pulmonary veno-occlusive disease and scleroderma associated pulmonary hypertension.

Authors:  Sindhu R Johnson; Demetris Patsios; David M Hwang; John T Granton
Journal:  J Rheumatol       Date:  2006-09-15       Impact factor: 4.666

5.  Left heart abnormalities in connective tissue disease patients with pre-capillary pulmonary hypertension as well as borderline mean pulmonary arterial pressure.

Authors:  Kosei Tsuchida; Hidehiro Yamada; Yoshioki Yamasaki; Kengo Suzuki; Ken Kongoji; Yoshihiro Akashi; Shoichi Ozaki
Journal:  Mod Rheumatol       Date:  2015-06-12       Impact factor: 3.023

6.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

7.  High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.

Authors:  Benjamin D Fox; Avi Shimony; David Langleben; Andrew Hirsch; Lawrence Rudski; Robert Schlesinger; Mark J Eisenberg; Dominique Joyal; Marie Hudson; Kim Boutet; Alexandrina Serban; Ariel Masetto; Murray Baron
Journal:  Eur Respir J       Date:  2012-12-20       Impact factor: 16.671

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

Authors:  Stephen C Mathai; Laura K Hummers; Hunter C Champion; Fredrick M Wigley; Ari Zaiman; Paul M Hassoun; Reda E Girgis
Journal:  Arthritis Rheum       Date:  2009-02

10.  Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.

Authors:  Inder Anand; John McMurray; Jay N Cohn; Marvin A Konstam; Thomas Notter; Kurt Quitzau; Frank Ruschitzka; Thomas F Lüscher
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

View more
  3 in total

1.  Protective Effects of Curcumin on Pulmonary Arterial Hypertension.

Authors:  Fatmeh Amin; Shiba Yousefvand; Tannaz Jamialahmadi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Role of curcumin in ameliorating hypertension and associated conditions: a mechanistic insight.

Authors:  Priyanka Joshi; Sushil Joshi; Deepak Kumar Semwal; Kanika Verma; Jaya Dwivedi; Swapnil Sharma
Journal:  Mol Cell Biochem       Date:  2022-05-15       Impact factor: 3.842

Review 3.  Pulmonary veno-occlusive disease: a probably underdiagnosed cause of pulmonary hypertension in systemic sclerosis.

Authors:  Ana Catarina Duarte; Ana Cordeiro; Maria José Loureiro; Filipa Ferreira
Journal:  Clin Rheumatol       Date:  2020-01-22       Impact factor: 2.980

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.